Intellia Therapeutics, Inc. NTLA
11.75
(0.41)
(3.37%)
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 0.0×
Follow NTLA
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (55.44%) | (56.34%) | (53.48%) | (52.11%) |
+8 more TTM periods Free account |
|
| (45.55%) | (45.23%) | (40.60%) | (42.49%) | ||
ROIC |
(91.28%) | (107.35%) | (124.43%) | (126.05%) | |
Return on Tangible Assets |
(86.29%) | (97.31%) | (93.48%) | (87.65%) | |
Average Days of Receivables |
44.91 | 50.43 | 51.07 | 70.11 | |
Free Cash Flow per Share |
(2.61) | (3.07) | (3.65) | (3.74) | |
Free Cash Flow |
(348.60) | (363.62) | (395.86) | (412.63) | |
Capital Expenditures |
(1.95) | (0.47) | (1.13) | (1.98) | |
Piotroski F-Score |
4.00 | 4.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(29.74%) | (36.43%) | (35.20%) | (32.60%) | |
Accounts Receivable Turnover |
6.37 | 6.73 | 7.53 | 5.78 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
582.68% | 546.47% | 574.63% | 725.01% | |
Selling, General and Administrative Expense of Revenue |
228.98% | 190.09% | 177.03% | 207.15% | |
Share Based Compensation of Revenue |
114.10% | 108.72% | 118.54% | 179.21% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.87 | 0.92 | 0.96 | 0.92 | |
Depreciation/Fixed assets |
1.01 | 1.01 | 0.90 | 0.61 | |
Capex/Depreciation |
(0.13) | (0.03) | (0.07) | (0.16) | |
Revenue per Share |
0.45 | 0.56 | 0.62 | 0.52 | |
Operating CF per Share |
(2.60) | (3.06) | (3.64) | (3.73) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.02) | |
Capex to Sales |
0.03 | 0.01 | 0.02 | 0.03 | |
Net Profit Margin |
(672.16%) | (597.04%) | (609.85%) | (774.94%) |
Columns are period end dates